mid-cap

Market Update On One Speciality Chemicals Stock - CRDA

Oct 15, 2024 | Team Kalkine

Read Time :10 Mins

Market Update On One Speciality Chemicals Stock - CRDA

CRDA:LSE
Investment Type

Mid - Cap
Risk Level
Action
Rec. Price (CA$)

Croda International PLC

Croda International PLC (LSE: CRDA) is an FTSE 100 listed entity that develops specialty chemicals.

H1 Unaudited Results (Released on 30 July 2024)

Group Performance: Croda's sales fell by 7.4%, from GBP 880.9 mn in the same period last year to GBP 815.9 mn, largely driven by the challenges in Life Sciences and Industrial Specialties. However, Consumer Care showed positive growth, especially in key markets like China and Asia, delivering a 9% increase in sales compared to the second half of 2023.

Life Sciences Decline: Life Sciences was heavily impacted by continued destocking in the Crop Protection and consumer health sectors, leading to a 19% decrease in sales. Despite these headwinds, Pharma sales, excluding CV19 lipids, showed a 3% increase over the second half of 2023.

Operating Margins: Adjusted operating profit margins fell from 20.0% to 16.6%, but there was a slight sequential improvement compared to the second half of 2023. This improvement was driven by higher sales volumes and robust cost-control measures.

Cash Flow and Debt: Croda delivered strong cash flow, with free cash flow rising by 69% to GBP 122.7 mn. Additionally, the company reduced its net debt to GBP 507.9 mn, reflecting its disciplined focus on capital and operational efficiency.

Share Price Chart

Markets are trading in a highly volatile zone currently due to certain macroeconomic issues and geopolitical tensions prevailing. Therefore, it is prudent to follow a cautious approach while investing.

Croda International PLC (LSE: CRDA) was trading at the current market price of GBX 3,815.00 (as of 15 October 2024, at 10:10 AM GMT+1)

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is 15 October 2024. The reference data in this report has been partly sourced from REFINITIV.

Note 3: ‘Kalkine reports are prepared based on the stock prices captured either from the London Stock Exchange (LSE) and or REFINITIV. Typically, both sources (LSE and or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.

Note 4: Dividend Yield may vary as per the stock price movement.

Small-Cap

A Watch on Datadog: Building Competitive Advantage Through Platform Consolidation and AI Adoption

Jun 25, 2026 Team Kalkine

Small-Cap

How SNDG Works: The Mechanics of the Leverage Shares 2X Long SNDK Daily ETF

Jun 25, 2026 Team Kalkine

Blue-Chip

AI-Driven Memory Leadership and Strategic Customer Agreements Strengthen Long-Term Growth Outlook: MU

Jun 25, 2026 Team Kalkine

Small-Cap

Technical Analysis One NASDAQ - Listed IT Services Stock- XNDU

Jun 25, 2026 Team Kalkine

Small-Cap

GCT Semiconductor: Advancing 5G Innovation Through Commercial Expansion and Strategic Partnerships

Jun 25, 2026 Team Kalkine

Disclaimer-

This report has been issued by Kalkine Limited (Company number 07903332), a private limited company, incorporated in England and Wales ("Kalkine”). Kalkine.co.uk and associated pages are published by Kalkine. Kalkine is authorised and regulated by the Financial Conduct Authority under reference number 579414.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain non personalized recommendations to invest in securities and other financial products.

Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall not be held liable for any investment or trading losses you may incur by using the opinions expressed in our reports, publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.

Please also read our Terms & Conditions for further information. Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this report or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Kalkine Media Limited, an affiliate of Kalkine, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this report.

Past performance is not a reliable indicator of future performance.